DSS Reiterates Plans for Impact BioMedical Share Dividend
Document Security Systems (DSS) has reaffirmed its plans for a two-part special share dividend of Impact BioMedical shares. Shareholders as of September 7, 2020, will receive two Bonus Shares for each DSS share held. The Bonus Shares will be distributed after Impact BioMedical's IPO, targeted for 2021. Although there are no guarantees regarding the IPO or share distribution due to market conditions, the company is committed to this path. Impact BioMedical, acquired by DSS in August 2020, holds antiviral technologies valued at $382 million.
- Shareholders will receive two shares of Impact BioMedical for each DSS share held as of September 7, 2020.
- The potential IPO of Impact BioMedical may enhance shareholder value.
- No guarantee that Impact BioMedical will complete its IPO or distribute Bonus Shares.
- Valuation discrepancies; initial valuation of $933 million was significantly reduced to $382 million.
ROCHESTER, N.Y., Sept. 22, 2020 (GLOBE NEWSWIRE) -- Document Security Systems, Inc. (“DSS” or the “Company”) (NYSE American: DSS), a multinational company operating businesses focusing on brand protection technology, blockchain security, direct marketing, healthcare, real estate, and securitized digital assets, reiterates its plans for its previously announced Impact BioMedical share dividend.
The first tranche of the two-part special share dividend was announced in August 2020, and DSS shareholders of record as of the record date of 5:00 p.m. ET on September 7, 2020 (“Record Date”) earned a bonus of two shares of Impact BioMedical (“Bonus Shares”) for every one share of DSS common stock held as of the Record Date. Shareholders are not required to hold their DSS shares beyond the Record Date to receive the Bonus Shares. The Bonus Shares are expected to be issued after an IPO of Impact BioMedical, which the Company is targeting in 2021.
While there can be no assurance that Impact BioMedical will be taken public and/or that any Bonus share distribution will occur, particularly due to unforeseen circumstances including fulfilling the pre-requisite criteria during the IPO application process and market forces beyond the Company's control, it is the intention of management and the Board to take Impact BioMedical public.
A second tranche of the special share dividend is expected to provide an additional two shares of Impact BioMedical for each common share of DSS held at a yet to be determined record date.
DSS announced the closing of its acquisition of Impact BioMedical on August 21, 2020. Impact BioMedical’s ownership of a suite of antiviral and medical technologies has been valued at
About Impact BioMedical, Inc.
Impact BioMedical, Inc. (“Impact BioMedical”) is a wholly owned subsidiary of DSS. Impact BioMedical strives to leverage its scientific know-how and intellectual property rights to provide solutions that have been plaguing the biomedical field for decades. By tapping into the scientific expertise of GRDG Sciences, LLC, Impact BioMedical pledges to undertake a concerted effort in the R&D, drug discovery and development for the prevention, inhibition, and treatment of neurological, oncological and immuno related diseases. For more information on Impact BioMedical visit http://impbio.com/.
About Document Security Systems, Inc.
DSS is a multinational company operating businesses focused on brand protection technology, blockchain security, direct marketing, healthcare, real estate, and securitized digital assets. Its business model is based on a distribution sharing system in which shareholders will receive shares in its subsidiaries as DSS strategically spins them out into IPOs. Its historic business revolves around counterfeit deterrent and authentication technologies, smart packaging, and consumer product engagement. DSS is led by its Chairman and largest shareholder, Mr. Fai Chan, a highly successful global business veteran of more than 40 years specializing in corporate transformation while managing risk. He has successfully restructured more than 35 corporations with a combined value of
For more information on DSS visit http://www.dsssecure.com.
Investor Contact:
Dave Gentry, CEO
RedChip Companies Inc.
407-491-4498
Dave@redchip.com
Safe Harbor Disclosure
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements include, but are not limited to, statements related to the Company's intended use of proceeds and other statements that are not historical facts. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that may cause actual results or events to differ materially from those projected. These risks and uncertainties, many of which are beyond our control, include: risks relating to our growth strategy; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; risks relating to the results of development activities; our ability to attract, integrate and retain key personnel; our need for substantial additional funds; patent and intellectual property matters; competition; as well as other risks described in the section entitled "Risk Factors" in the prospectus and in our other filings with the SEC, including, without limitation, our reports on Forms 8-K and 10-Q, all of which can be obtained on the SEC website at www.sec.gov. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management's current estimates, projections, expectations and beliefs. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.
FAQ
What is the DSS Impact BioMedical share dividend?
When is the Impact BioMedical IPO expected?
How much is the Impact BioMedical technology suite valued at?
Are there any risks associated with the Dividend?
